Curcumin (CUR), a widely used
food additive, is derived mainly from Curcuma species that has been applied traditionally for the treatment of various diseases, including
hepatocellular carcinoma (HCC). However, its poor systemic bioavailability hampers its clinical application, which may be related to its wide metabolism.
Tetrahydrocurcumin (
THC) is a major metabolite of CUR and has been reported to have multiple
biologic activities. We investigated, for the first time, the efficacy and associated mechanism of action of
THC and CUR in a H22
ascites tumor-bearing model in mice.
THC evoked a significant dose-dependent promotion of survival and was significantly more effective than CUR in inhibiting
tumor growth, including increased
body weight, abdominal circumference,
ascites volume, and the viability of
cancer cells. Experiments on essential immune organs indicated that
THC had a more favorable margin of safety than the reference
drug cyclophosphamide.
THC induced the apoptosis of H22 cells obviously by increasing the level of p53 and decreasing the level of murine double minute 2.
THC also decreased the expression of Bcl-2 significantly and increased the expression of Bcl2-associated X, resulting in the release of
cytochrome C.
THC significantly activated and induced cleavage of
caspase-3 and
caspase-9 to induce the apoptosis of H22 cells. Taken together, these results indicate that
THC was more effective than CUR in inhibiting the apoptosis of H22-induced
ascites tumor cells and achieved it via regulation of a mitochondrial apoptosis pathway.
THC might be a bioactive anti-
tumor form of CUR and represented a potentially effective agent for HCC treatment.